Ads
related to: heart disease, cancer drug- Managing Patient LDL-C
Discover Nine Important Modifiable
Heart Attack Risk Factors.
- ASCVD Patients
Find How To Identify Your Patients
Risk Status. Learn More.
- LDL-C Testing Options
See LDL-C Testing Recommendations.
Learn More About Testing Options.
- For Your ASCVD Patients
Identify Your Patients' Risk Status
Based on Risk Factors. Learn More.
- Managing Patient LDL-C
Search results
Scientists Are Studying Weight-Loss Drugs for Way More Than Weight Loss
Time via AOL· 17 hours agoKidney disease People with diabetes often develop kidney complications. Those taking the drug...
Lung cancer risks remain high for smokers who switch to vaping
UPI· 15 hours agoFolks who'd quit smoking for five years or more but were vaping still faced higher odds for fatal...
Olivia Munn documented cancer journey for son to show him 'I tried my best' if she 'didn't make it'
Fox News· 3 days agoOlivia Munn opened up about why she decided to document her cancer journey. Munn said that she...
Recent FDA Committee Vote Could Speed Multiple Mye | Newswise
Newswise· 1 day agoA U.S. Food and Drug Administration committee voted unanimously in April to approve a new clinical...
What Causes Blood Clots in Lungs (Pulmonary Embolism)?
Health via Yahoo News· 5 days agoMedical History Some conditions are associated with a higher risk of developing deep vein thrombosis...
What's the Difference Between Vegetarian and Pescatarian Diets?
Health via Yahoo News· 15 hours agoFoods are simply seasoned, and small amounts of lean meats, chicken, and eggs are also included....
Signs of Alzheimer’s were everywhere. Then his brain improved | CNN
CNN.com· 3 days agoSanjay Gupta is a practicing neurosurgeon and best-selling author on brain health. Preventive...
Weight Loss Drug Can Sustain Results For Up To 4 Years And May Protect Hearts Too
IFLScience· 5 days agoWegovy, an injectable prescription weight loss drug, can produce effective results that help patients keep weight off for up to four years, a new study suggests. The
AstraZeneca sets sights on $80B in revenue by 2030
BioPharma Dive via Yahoo Finance· 19 hours agoTwo trial readouts for new cardiovascular drugs are coming in 2025, while an antibody-drug conjugate called datopotamab deruxtecan is in late-stage...
Council Post: Go Forth, And Fight Aging
Forbes· 1 day agoRecently, he shared a paper in Nature Biotechnology with his hundreds of thousands of Twitter followers about a new drug, designed by AI, for the rare...